FDA Devices Approval | 2024 | Abbott News | iPharmaCenter

FDA Diagnostics Approvals | 2024 | FDA Approvals | iPharmaCenter

Centers for Disease Control and Prevention | CDC | iPharmaCenter | 2024

Express-Scripts | Pharmacy Benefit Manager | News | Updates | 2024 | US Healthcare | iPharmaCenter

Eisai's Leqembi received FDA approval for Alzheimer's | CMS coverage of Leqembi | ipharmacenter

COVID19 drug updates | FDA EMA approved COVID19 drugs

Genzyme's Xenpozyme approved for Acid Sphingomyelinase Deficiency | iPharmaCenter

Lilly's and Incyte's Olumiant approved for adults with severe alopecia areata

Myasthenia Gravis News | FDA and EMA approvals |

American College of Rheumatology (ACR) Convergence all-virtual annual meeting Updates

FDA approved Novartis Scembli for chronic myeloid leukemia

Biogen's Aduhelm received FDA approval for Alzheimer's disease; ICER criticized approval

GSK’s Jemperli received approval in Europe and the US for endometrial cancer

US FDA approved BMS gene therapy Breyanzi

Novartis and BeiGene collaboration strengthens the Swiss drugmaker's oncology portfolio

REGENERON'S INMAZEB FIRST PRODUCT TO RECEIVE FDA APPROVAL FOR TREATING EBOLA VIRUS